Featured Research

from universities, journals, and other organizations

Gallium: A New Antibacterial Agent?

Date:
March 16, 2007
Source:
Journal of Clinical Investigation
Summary:
New antibacterial strategies are needed because more and more bacteria are antibiotic resistant and because antibiotics are not effective at eradicating chronic bacterial infections. In a new study, using Gallium (Ga) to limit the amount of iron (Fe) to which bacteria have access protected mice from both acute and chronic Pseudomonas aeruginonsa lung infections, leading to the suggestion that Ga might be a promising new therapeutic for the treatment of infection with P. aeruginonsa.

New antibacterial strategies are needed because more and more bacteria are antibiotic resistant and because antibiotics are not effective at eradicating chronic bacterial infections. One approach to developing new antibacterial strategies, taken by researchers from the University of Washington, Seattle, is to limit the amount of iron (Fe), which is critical for bacterial growth, to which bacteria have access.

In the study, which appears online on March 15 in advance of publication in the April print issue of the Journal of Clinical Investigation, Pradeep Singh and colleagues show that Gallium (Ga), which is chemically similar to Fe and can disrupt biological systems by substituting for Fe, inhibits the in vitro growth of Pseudomonas aeruginonsa; even multidrug resistant strains of P. aeruginonsa isolated from individuals with cystic fibrosis.

Ga also prevented P. aeruginonsa forming biofilms, the multi-cellular bacterial communities responsible for chronic bacterial infections, and killed both free-living bacteria and bacteria in biofilms. Furthermore, inhalation of Ga protected mice from both acute and chronic P. aeruginonsa lung infections.

As Ga is already FDA approved for the treatment of hypercalcemia of malignancy, these data suggest that Ga might be a promising new therapeutic for the treatment of infection with P. aeruginonsa, a major cause of infection in individuals with cystic fibrosis and of infection acquired in hospital.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Gallium: A New Antibacterial Agent?." ScienceDaily. ScienceDaily, 16 March 2007. <www.sciencedaily.com/releases/2007/03/070315210325.htm>.
Journal of Clinical Investigation. (2007, March 16). Gallium: A New Antibacterial Agent?. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/03/070315210325.htm
Journal of Clinical Investigation. "Gallium: A New Antibacterial Agent?." ScienceDaily. www.sciencedaily.com/releases/2007/03/070315210325.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins